ENVI Committee adopts a report on the Pharmaceutical Strategy for Europe

The European Parliament's Committee on Environment, Public Health and Food Safety (ENVI) adopted a Pharmaceutical Strategy.

The European Parliament's Committee on Environment, Public Health and Food Safety (ENVI) meetings held on 11-12 October, during which the own initiative report (INI) on a Pharmaceutical Strategy for Europe was adopted. After weeks of negotiations, the MEPs agreed on 35 compromise amendments (originally, 723 amendments were published).

The concerning amendments are:

  • Greater involvement of patients’ organisations in drug development and pharmaceutical research strategies to address unmet therapeutic needs.
  • Assess and review the existing incentives framework and stimulate competition by adapting the regulatory framework.
  • Europe to become worldwide centre of excellence for R&D in emerging, innovative fields of medicine.
  • The importance of aligning the current legislation with scientific progress in the development of therapeutic applications of nuclear medicine.
  • The need for a stable and predictable regulatory environment, limiting administrative burden, safeguarding safe, effective and quality medicines on the EU market.
  • A consistent application and enforcement of the GDPR in all EU Member to build the European Health Data Space and leverage the full potential of real-world-data and access to rare therapies.

On 25 November 2020, the Commission published a Communication on a Pharmaceutical Strategy for Europe, a key tool to ensure that EU’s pharmaceutical policy continues to serve public health. Its goal is to give the EU's pharmaceutical policy a long-term vision: to ensure it is crisis-resilient and sustainable, and to reinforce EU's position as a global leader while ensuring access to affordable medicines for patients.



Date: 22/10/2021 | Tag: | News: 1234 of 1626
All news

News

  • 05/11/2024

    "In silico trials: an updated SWOT Analysis" released by In Silico World

    • The document comprehensively examines the strengths, weaknesses, opportunities, and threats for In Silico Trials in healthcare, providing a roadmap to help biomedical companies navigate and adopt these innovative methodologies. -Read more-
  • 31/10/2024

    In the literature: October 2024 highlights

    • Click here to read some interesting recently published papers from our community. If you have published an article in the field of in silico medicine, send it to us: we will include it in this section of the newsletter! -Read more-
  • 31/10/2024

    Joint motion for a resolution to revise the Medical Devices Regulation

    • The European Parliament has voted with a large majority to urge the European Commission to implement critical amendments to the EU Medical Device Regulation (MDR) by the first quarter of 2025. The drive for reform is intended to tackle pressing issues in the regulation, which has been criticised for its excessive bureaucracy and impact on patient care, jobs, and innovation in the medical device sector. -Read more-
  • 31/10/2024

    EU Budget for 2025 Prioritizes Research, Health, Education, and Climate Action

    • The European Parliament has presented their draft budget demanding an EU budget for 2025 that focuses on improving people's lives, boosting competitiveness, and addressing current challenges. MEPs are proposing a budget of nearly €201 billion, which exceeds the European Commission's initial proposal of around €199.76 billion. -Read more-
More news

Events

More events
newsletter

Subscribe to the VPH Institute Newsletter

ARCHIVE

Read all the newsletters of the VPH Institute

GO